Evaluation and Comparison of Mucormycosis Patients’ Features Undergoing Functional Endoscopic Sinus Surgery Prior to and during the COVID-19 Pandemic: A Case-Control Study

Laleh Dehghanpisheh, Mohammadhossein Eghbal, Mehrdad Salari, Reza Shahriarirad, Niloofar Borzou, and Pooya Vatankhah

1Anesthesiology and Critical Care Research Center, Department of Anesthesiology and Critical Care, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2Thoracic and Vascular Surgery Research Center, Shiraz University of Medical Science, Shiraz, Iran

Correspondence should be addressed to Pooya Vatankhah; pvatankhah@sums.ac.ir

Received 20 February 2022; Revised 19 April 2022; Accepted 14 May 2022; Published 7 June 2022

Academic Editor: Manish Gupta

Copyright © 2022 Laleh Dehghanpisheh et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Rhinocerebral mucormycosis is a serious invasive fungal infection that is one of the most aggressive and lethal of invasive mycoses. The coronavirus disease (COVID-19) has been linked to immune dysregulation, and patients with COVID-19 have been reported to be at risk for developing invasive fungal infections. This study is conducted to evaluate the concurrence of mucormycosis among COVID-19 patients.

Methods. In this retrospective, cross-sectional study, hospital records of patients with mucormycosis, as well as COVID-19 admitted to Khalili Hospital, as the major referral center for functional endoscopic sinus surgery (FESS) in southern Iran, were collected. Demographic and clinical information was extracted and subsequently analyzed. Results. Among 59 mucormycosis patients undergoing FESS, 41 (69.5%) were during the COVID-19 pandemic, while 18 (30.5%) were during one year before the COVID-19 pandemic. The average age was 49.33 ± 20.52, and 64.4% had diabetes mellitus, while 62.7% had COVID-19. The most common presentation was periorbital edema (56.9%), followed by necrotic tissue (48.3%). Although the total number of cases increased during the COVID-19 period compared to the case before the pandemic, the overall pattern and features of the patients had no significant difference, except regarding a significant increase in the presentation of necrotic tissue and also the use of corticosteroids. Most cases developed mucormycosis two weeks after COVID-19. The overall mortality was 36.8%, which is not statistically associated with COVID-19. Conclusion. Even in the absence of comorbidities, physicians should be aware of the risk of secondary fungal infections in patients with COVID-19 who were treated with corticosteroids.

1. Background

Mucormycosis is an invasive fungal infection that most commonly affects diabetic and immunocompromised patients, particularly in its rhino-orbital-cerebral or pulmonary forms. Rarely, mucormycosis may involve the trachea and main bronchi [1,2]. Mucormycosis is an opportunistic infection that usually involves diabetic patients (with or without ketoacidosis), cases with hematologic malignancies or organ transplantation, and patients who are on iron chelator or broad-spectrum antibiotics. The most common form of pulmonary involvement in mucormycosis is pneumonic infiltration with variable and somewhat characteristic radiologic features [1,2]. The involvement of large airways with or without parenchymal disease is less common [1,2].

Rhinocerebral mucormycosis is a serious invasive fungal infection that is one of the most aggressive and lethal of invasive mycoses. Uncontrolled diabetes, organ transplant, malignancies such as lymphoma and leukemia, immunosuppressive therapy, renal failure, and acquired immune deficiency syndrome (AIDS) are all underlying diseases for
mucormycosis [3]. Disseminated rhino-orbital-cerebral mucormycosis is a lethal invasive fungal infection that accounts for 8.3–13 percent of all fungal infections found in hematological patients’ autopsies. Hematological malignancy, immunosuppressed children, and Diabetic ketoacidosis (DKA) are all predisposing factors. Uncontrolled diabetes mellitus, periorbital infection, and meningencephalitis are all part of the mucormycosis triad [4].

The ongoing COVID-19 outbreak began in December 2019 in Wuhan, China. COVID-19, the disease linked to SARS-CoV-2 infection, spread quickly, resulting in a global pandemic [5]. The severity of symptoms associated with SARS-CoV-2 infection ranges from mild to severe [6, 7]. The proportion of infections that are severe or fatal varies by location. COVID-19 patients may have elevated levels of inflammatory cytokines (such as interleukin [IL]-2R, IL-6, IL-10, and tumor necrosis factor-alpha), as well as a weakened cell-mediated immune response, affecting both CD4+ T and CD8+ T cells. As a result, there is an increased susceptibility to fungal coinfections [8]. Also, comorbid diseases and conditions such as immunodeficiency, diabetes, and transplantation can act as a risk factor for both COVID-19 and other types of bacterial or fungal infections [7, 9–12]. COVID-19 and acute respiratory failure are treated with a combination of broad-spectrum antibiotics and corticosteroids (both of which are risk factors for invasive fungal disease) [13]. COVID-19 has been linked to immune dysregulation [14], and patients with COVID-19 have been reported to be at risk for developing invasive fungal infections like invasive aspergillosis, candidiasis, and Pneumocystis jiroveci infection [15, 16]. However, the consequences of the impact of the COVID-19 pandemic, along with diagnostic and management challenges, remain [17–22].

Infarction and necrosis of the host tissues are symptoms of mucormycosis, which is caused by hyphae invading the vasculature. Mucormycosis can present as a variety of syndromes depending on the anatomic site involved, including rhino-orbital-cerebral, pulmonary, cutaneous, and less commonly GI, renal, and disseminated diseases [23].

Surgical debridement of the affected tissues and antifungal therapy is used to treat the condition. The drug of choice for initial therapy is intravenous amphotericin B (a lipid formulation) [24]. The prognosis for recovery from mucormycosis is poor despite early diagnosis and aggressive combined surgical and medical therapy [25]. Effective management consists of cytological diagnosis, optimization of predisposing conditions, systemic antifungal therapy with prompt, and surgical debridement of infected tissue, via methods such as functional endoscopic sinus surgery (FESS) [4].

The ability to cure the condition depends on clinical suspicion and early therapy. As a result, if symptoms imply mucormycosis, preemptive medication should be explored. More studies are necessary to determine if these two pathologies are related. Therefore, this study is conducted to evaluate the features of patients who underwent FESS due to mucormycosis and its concurrence with COVID-19 patients in Southern Iran.

2. Material and Methods

In this retrospective, cross-sectional study, all patients who underwent FESS due to mucormycosis and had not responded to medical treatment from April 2020 till September 2021 were included in our study. Patients with the diagnosis of mucormycosis were initially administered intravenous liposomal amphotericin B 5–10 mg/kg/day, followed by step-down therapy with Posaconazole [24, 26]. Patients who did not have sufficient response to medical treatment, such as the persistence or progression of signs and symptoms, or positive necrosis in their biopsy were scheduled for FESS. Data of these patients were retrieved from the archives of Khalili Hospital, which is the major referral center in southern Iran for FESS. Hospital records extraction was carefully based on the specific disease code. Demographic information, case number, and place of residence and information related to disease, age, sex, length of hospital stay, symptoms, underlying disease, hospital stay, need for intubation, and need for chest tube insertion of patients with mucormycosis, were extracted, and information regarding COVID-19 (based on clinical symptom criteria, chest CT scan, and positive report of COVID-19 test based on Rt-PCR SARS-CoV-2) was used for the extraction, where this information was subsequently statistically analyzed.

The present study was approved by the Medical Ethics Committee of Shiraz University of Medical Sciences. The study was conducted in compliance with local regulatory requirements, Good Clinical Practice (GCP), and the Declaration of Helsinki and according to the STROBE checklist. Due to the retrospective nature of our study, informed consent was not obtained from the patients, and the Ethics committee of Shiraz University of Medical Sciences waived the need for informed consent. The patients’ information was documented from their hospital records. Patients’ data were anonymized prior to analysis, and their confidentiality was secured by the researcher. All study protocols and data collection were performed in accordance with the Declaration of Helsinki and approved by the mentioned ethics committee.

The data was analyzed using IBM Corporation’s SPSS software version 22 (Armonk, NY). The Kolmogorov-Smirnov normality test was used to determine whether the data were normal. Data analysis was carried out using independent sample students’ t-test and ANOVA test for continuous variables and chi-square for categorical variables after validation of the parameters’ normal distribution. Frequency, percentage, mean data distribution, and standard deviation are components of descriptive statistics (SD).

3. Results

During the period of our study, a total of 59 cases of mucormycosis who underwent FESS were documented. Among the patients, 41 (69.5%) were during the COVID-19 pandemic, while 18 (30.5%) were during one year before the COVID-19 pandemic. Figure 1 demonstrates the frequency of cases during the timeline of our study, along with a comparison with the total number of COVID-19 cases in our study area.
Among the patients, 55 (93.2%) had comorbid diseases, in which diabetes mellitus was the most prevalent comorbidity among our patients. The patients’ age ranged from 2.5 years to 80 years old. The overall features of the patients are demonstrated in Table 1. Also, 37 (62.7%) of our patients had COVID-19.

The most common presentation in our patients was periorbital edema (56.9%), followed by necrotic tissue (48.3%). Also, the most common comorbidity was diabetes mellitus (64.4%). As demonstrated in Table 1, based on the two timelines in our study, although the total number of cases increased during the COVID-19 period compared to the case before the pandemic, the overall pattern and features of the patients had no significant difference, except regarding a significant increase in the presentation of necrotic tissue, and also the use of corticosteroids (P = 0.003 and 0.001, respectively). While comparing the COVID-19 group with the noninfected group, there was only a significantly higher number of diabetic patients with COVID-19, compared to non-COVID-19 diabetic patients (P = 0.026). Also, COVID-19 patients demonstrated a significantly higher frequency of necrotic tissue compared to the non-COVID-19 group (P = 0.016).

The patient’s hospitalization features are demonstrated in Table 2. Based on CT-scan evaluation, 24 (64.9%) of the patients had features in favor of COVID-19, while 2 (5.4%) of the COVID-19 patients had normal CT scans.

We evaluated the hospitalization and illness course of the patients in our study (Table 2). The average hospitalization duration following FESS did not change during the COVID-19 pandemic, while also there was no statistically significant difference regarding the patients’ vital signs based on COVID-19.

Regarding the radiological evaluation of the patients, the most frequent finding in the PNS CT was mucosal thickening (51.7%) followed by sinusitis (48.3%), which did not alter during and prior to the COVID-19 pandemic or among COVID-19 positive and negative patients.

Based on laboratory evaluation, there were no significant differences regarding white blood cell count and differentiation or hemoglobin count based on COVID-19 among our patients. However, COVID-19 patients had significantly lower platelet counts compared to the non-COVID-19 group (P < 0.001).

Regarding ventilation, the majority of our patients did not require any supportive ventilation (64.9%), which was also similar among the COVID-19 and non-COVID-19 groups; however, 10.5% of the patients required intubation, which also was not related to COVID-19.

Based on the performed operation among our patients, 19 (32.2%) required additional operations such as maxillectomy, orbital exenteration, and frontal lobectomy, aside from FESS. Also, the mortality rate in our study was 21 (36.8%) cases, which was unrelated to COVID-19. There was also no significant association between the duration of symptoms and the patient’s outcome (P = 0.685).

As demonstrated in Table 2, the number of patients presenting with mucormycosis on admission was significantly higher among COVID-19 patients (P = 0.040). Most cases developed mucormycosis two weeks after COVID-19.

4. Discussion

Early identification, management of the underlying disease, administration of antifungal medication (such as amphotericin B), radical surgical debridement, and other adjuvant treatments are all important factors in improving
| Variable | Total; N = 59 | Timeline | COVID-19 | P value* | Not infected; N = 22 | Infected; N = 37 | P value* |
|----------|--------------|----------|----------|----------|-----------------------|-----------------|----------|
| Age      | 49.33 ± 20.52 | 39.86 ± 25.69 | 53.49 ± 16.50 | 0.050 | 37.11 ± 24.57 | 56.59 ± 13.45 | 0.002   |
| Gender   |              |          |          |          |                       |                 |         |
| Male     | 37 (62.7)    | 10 (55.6) | 27 (65.9) | 0.451 | 11 (50.0) | 26 (70.3) | 0.166   |
| Female   | 22 (37.3)    | 8 (44.4)  | 14 (34.1) |          | 11 (50.0) | 11 (29.7) |          |
| Diabetes mellitus | 38 (64.4)      | 9 (50.0)  | 29 (70.7) | 0.149 | 10 (45.5) | 28 (75.7) | 0.026   |
| Hypertension | 31 (52.5)      | 7 (39.8)  | 24 (58.5) | 0.257 | 8 (36.4) | 2 (62.2) | 0.065   |
| Cardiovascular | 11 (18.6)      | 3 (16.7)  | 8 (19.5)  | 1.000 | 2 (9.1) | 9 (24.3) | 0.184   |
| Cerebrovascular Dx | 10 (16.9)      | 3 (16.7)  | 7 (17.1)  | 1.000 | 2 (9.1) | 8 (21.6) | 0.294   |
| Malignancy | 9 (15.3)       | 4 (22.2)  | 5 (12.2)  | 0.434 | 4 (18.2) | 5 (13.5) | 0.715   |
| Chronic kidney Dx | 8 (13.6)       | 2 (11.1)  | 6 (14.6)  | 1.000 | 1 (4.5) | 7 (18.9) | 0.237   |
| Comorbid disease |              |          |          |          |                       |                 |         |
| Diabetes mellitus | 38 (64.4)      | 9 (50.0)  | 29 (70.7) | 0.149 | 10 (45.5) | 28 (75.7) | 0.026   |
| Hypertension | 31 (52.5)      | 7 (39.8)  | 24 (58.5) | 0.257 | 8 (36.4) | 2 (62.2) | 0.065   |
| Cardiovascular | 11 (18.6)      | 3 (16.7)  | 8 (19.5)  | 1.000 | 2 (9.1) | 9 (24.3) | 0.184   |
| Cerebrovascular Dx | 10 (16.9)      | 3 (16.7)  | 7 (17.1)  | 1.000 | 2 (9.1) | 8 (21.6) | 0.294   |
| Malignancy | 9 (15.3)       | 4 (22.2)  | 5 (12.2)  | 0.434 | 4 (18.2) | 5 (13.5) | 0.715   |
| Chronic kidney Dx | 8 (13.6)       | 2 (11.1)  | 6 (14.6)  | 1.000 | 1 (4.5) | 7 (18.9) | 0.237   |
| Gender   |              |          |          |          |                       |                 |         |
| Male     | 37 (62.7)    | 10 (55.6) | 27 (65.9) | 0.451 | 11 (50.0) | 26 (70.3) | 0.166   |
| Female   | 22 (37.3)    | 8 (44.4)  | 14 (34.1) |          | 11 (50.0) | 11 (29.7) |          |
| Comorbid disease |              |          |          |          |                       |                 |         |
| Diabetes mellitus | 38 (64.4)      | 9 (50.0)  | 29 (70.7) | 0.149 | 10 (45.5) | 28 (75.7) | 0.026   |
| Hypertension | 31 (52.5)      | 7 (39.8)  | 24 (58.5) | 0.257 | 8 (36.4) | 2 (62.2) | 0.065   |
| Cardiovascular | 11 (18.6)      | 3 (16.7)  | 8 (19.5)  | 1.000 | 2 (9.1) | 9 (24.3) | 0.184   |
| Cerebrovascular Dx | 10 (16.9)      | 3 (16.7)  | 7 (17.1)  | 1.000 | 2 (9.1) | 8 (21.6) | 0.294   |
| Malignancy | 9 (15.3)       | 4 (22.2)  | 5 (12.2)  | 0.434 | 4 (18.2) | 5 (13.5) | 0.715   |
| Chronic kidney Dx | 8 (13.6)       | 2 (11.1)  | 6 (14.6)  | 1.000 | 1 (4.5) | 7 (18.9) | 0.237   |
| Age      | 49.33 ± 20.52 | 39.86 ± 25.69 | 53.49 ± 16.50 | 0.050 | 37.11 ± 24.57 | 56.59 ± 13.45 | 0.002   |
| Gender   |              |          |          |          |                       |                 |         |
| Male     | 37 (62.7)    | 10 (55.6) | 27 (65.9) | 0.451 | 11 (50.0) | 26 (70.3) | 0.166   |
| Female   | 22 (37.3)    | 8 (44.4)  | 14 (34.1) |          | 11 (50.0) | 11 (29.7) |          |
| Comorbid disease |              |          |          |          |                       |                 |         |
| Diabetes mellitus | 38 (64.4)      | 9 (50.0)  | 29 (70.7) | 0.149 | 10 (45.5) | 28 (75.7) | 0.026   |
| Hypertension | 31 (52.5)      | 7 (39.8)  | 24 (58.5) | 0.257 | 8 (36.4) | 2 (62.2) | 0.065   |
| Cardiovascular | 11 (18.6)      | 3 (16.7)  | 8 (19.5)  | 1.000 | 2 (9.1) | 9 (24.3) | 0.184   |
| Cerebrovascular Dx | 10 (16.9)      | 3 (16.7)  | 7 (17.1)  | 1.000 | 2 (9.1) | 8 (21.6) | 0.294   |
| Malignancy | 9 (15.3)       | 4 (22.2)  | 5 (12.2)  | 0.434 | 4 (18.2) | 5 (13.5) | 0.715   |
| Chronic kidney Dx | 8 (13.6)       | 2 (11.1)  | 6 (14.6)  | 1.000 | 1 (4.5) | 7 (18.9) | 0.237   |
| Age      | 49.33 ± 20.52 | 39.86 ± 25.69 | 53.49 ± 16.50 | 0.050 | 37.11 ± 24.57 | 56.59 ± 13.45 | 0.002   |
| Gender   |              |          |          |          |                       |                 |         |
| Male     | 37 (62.7)    | 10 (55.6) | 27 (65.9) | 0.451 | 11 (50.0) | 26 (70.3) | 0.166   |
| Female   | 22 (37.3)    | 8 (44.4)  | 14 (34.1) |          | 11 (50.0) | 11 (29.7) |          |
| Variable | Total; $N = 59$ | Non-COVID-19 period; $n = 18$ | COVID-19 period; $n = 41$ | $P$ value$^a$ | Not infected; $n = 22$ | Infected; $n = 37$ | $P$ value$^a$ |
|----------|----------------|-------------------------------|-----------------------------|----------------|-------------------------|----------------|----------------|
| Hospitalization duration | 1.12 ± 0.42 | 1.16 ± 0.51 | 1.10 ± 0.38 | 0.582 | 1.14 ± 0.47 | 1.11 ± 0.40 | 0.827 |
| SPO2 on admission | 96.07 ± 8.34 | 95.76 ± 5.61 | 96.20 ± 2.89 | 0.701 | 96.59 ± 5.05 | 95.75 ± 2.90 | 0.423 |
| Temperature on admission | 36.60 ± 0.37 | 36.77 ± 0.46 | 36.52 ± 0.29 | 0.047 | 36.67 ± 0.38 | 36.56 ± 0.36 | 0.243 |
| Blood pressure on admission | | | | | | | |
| Systolic | 125.52 ± 16.21 | 121.88 ± 13.84 | 126.98 ± 17.01 | 0.292 | 123.16 ± 13.92 | 126.73 ± 17.32 | 0.440 |
| Diastolic | 76.54 ± 13.05 | 72.75 ± 17.89 | 78.05 ± 10.43 | 0.172 | 75.32 ± 10.87 | 77.16 ± 14.14 | 0.621 |
| Respiratory rate on admission | 18.86 ± 2.56 | 18.59 ± 3.00 | 18.98 ± 2.39 | 0.605 | 19.33 ± 2.71 | 8.59 ± 2.48 | 10.296 |
| Heart rate on admission | 87.86 ± 15.24 | 93.94 ± 19.18 | 85.20 ± 12.50 | 0.041 | 90.23 ± 18.29 | 86.46 ± 13.17 | 0.363 |
| Mucormycosis on admission | | | | | | | |
| Yes | 42 (71.2) | 13 (72.2) | 29 (70.7) | 1.000 | 12 (54.5) | 30 (81.1) | 0.040 |
| No | 17 (28.8) | 5 (27.8) | 12 (29.3) | 1 (4.5) | 7 (18.9) | | |
| Mucormycosis diagnosis duration from admission | 8.38 ± 6.02 | 7 ± 6.08 | 6.75 ± 4.65 | 0.738 | 7 ± 6.08 | 8.5 ± 6.09 | 0.738 |
| Lung CT finding | | | | | | | |
| Ground glass opacities | 24 (61.5) | 0 (0) | 24 (61.5) | <0.001 | 2 (22.2) | 22 (73.3) | 0.015 |
| Interlobular septal thickening | 9 (23.1) | 1 (12.5) | 8 (25.8) | 0.653 | 0 (0) | 9 (30.0) | 0.085 |
| Cardiomegaly | 2 (5.1) | 0 (0) | 2 (6.5) | 1.000 | 0 (0) | 2 (6.7) | 1.000 |
| PNS CT | | | | | | | |
| Total performed | 29 (49.2) | 13 (72.2) | 16 (39.0) | 0.025 | 10 (45.5) | 19 (51.4) | 0.789 |
| Mucormycosis or fungal infection | 8 (27.6) | 3 (23.1) | 5 (31.3) | 0.697 | 2 (20.0) | 6 (31.6) | 0.675 |
| Mucosal thickening | 15 (51.7) | 4 (30.8) | 11 (68.8) | 0.066 | 3 (30.0) | 12 (63.2) | 0.128 |
| Sinusitis | 14 (48.3) | 7 (53.8) | 7 (43.8) | 0.715 | 6 (60.0) | 8 (42.1) | 0.450 |
| Bone erosion or destruction | 6 (20.7) | 3 (23.1) | 3 (18.8) | 1.000 | 1 (10.0) | 5 (26.3) | 0.633 |
| Soft tissue mass | 5 (17.2) | 1 (7.7) | 4 (25.0) | 0.343 | 3 (30.0) | 2 (10.5) | 0.306 |
| Soft tissue swelling | 3 (10.3) | 1 (7.7) | 2 (12.5) | 1.000 | 0 (0) | 3 (15.8) | 0.532 |
| Orbital CT | | | | | | | |
| Total performed | 8 (13.6) | 0 (0) | 8 (19.5) | 0.092 | 2 (9.1) | 6 (16.2) | 0.697 |
| or fungal infection | 3 (37.5) | 0 (0) | 3 (100) | | 0 (0) | 3 (50.0) | 0.464 |
| Sinusitis | 4 (50.0) | 0 (0) | 4 (100) | — | 2 (100) | 2 (33.3) | 0.429 |
| Cellulitis | 2 (25.0) | 0 (0) | 2 (100) | — | 0 (0) | 2 (33.3) | 1.000 |
| Proptosis | 1 (12.5) | 0 (0) | 1 (100) | — | 0 (0) | 1 (16.7) | 1.000 |
| PNS and orbital MRI | | | | | | | |
| Total performed | 1 (1.7) | 1 (5.6) | 0 (0) | 0.305 | 1 (4.5) | 0 (0) | — |
| Sinusitis | 1 (100) | 1 (100) | 0 (0) | — | 1 (4.5) | 0 (0) | — |
| Scalp enhancement | 1 (100) | 1 (100) | 0 (0) | — | 1 (4.5) | 0 (0) | — |
| Globe protrusion | 1 (12.5) | 1 (100) | 0 (0) | — | 1 (100) | 0 (0) | 1.000 |
| Laboratory data | | | | | | | |
| White blood cell count | 11.70 ± 5.77 | 11.82 ± 6.25 | 11.56 ± 5.44 | 0.908 | 11.80 ± 5.94 | 11.59 ± 5.80 | 0.923 |
| Lymphocyte count | 24.91 ± 20.25 | 2.40 ± 1.93 | 1.76 ± 1.19 | 0.397 | 2.21 ± 2.14 | 2.11 ± 1.31 | 0.910 |
| Neutrophil count | 70.55 ± 19.12 | 7.34 ± 3.39 | 7.93 ± 4.98 | 0.802 | 7.74 ± 5.18 | 7.42 ± 2.93 | 0.894 |
| Hemoglobin count | 10.94 ± 2.37 | 10.73 ± 2.65 | 11.06 ± 2.24 | 0.659 | 10.56 ± 2.49 | 11.26 ± 2.28 | 0.330 |
| Platelet count | 281.76 ± 201.89 | 364.53 ± 285.15 | 225.31 ± 86.22 | 0.086 | 375.29 ± 258.53 | 202.25 ± 80.36 | 0.016 |
| RT-PCR | | | | | | | |
| Positive | 33 (58.9) | 0 (0) | 33 (80.49) | <0.001 | 0 (0) | 33 (94.3) | <0.001 |
| Ventilation | | | | | | | |
| Room air | 37 (64.9) | 11 (68.8) | 26 (63.4) | 1 (8.0) | 17 (81.0) | 20 (55.6) | |
| Noninvasive or nasal mask | 14 (24.6) | 2 (12.5) | 12 (29.3) | 0.239 | 2 (9.5) | 12 (33.3) | 0.113 |
| Invasive and intubation | 6 (10.5) | 3 (18.8) | 3 (7.3) | 2 (9.5) | 4 (11.1) | | |
| Chest tube insertion | 2 (3.8) | 0 (0) | 2 (5.1) | 1.000 | 0 (0) | 2 (5.7) | 0.543 |
rhinocerebral mucormycosis survival [27–29]. Early diagnosis is critical because it allows for more rapid implementation of appropriate treatment [30]. Early diagnosis relies on the patient seeking medical treatment as soon as possible, the physician’s suspicion of the condition, and the pathologist’s definitive confirmation of the diagnosis [31]. When a diagnosis is delayed, it is impossible to provide prompt and effective therapy. The most challenging and crucial component of treatment may be maintaining control of the underlying condition. When a number of predisposing variables play a role in the development of rhinocerebral mucormycosis, early detection and treatment of these factors are critical for survival. The prognosis differs depending on the underlying condition [27]. Diabetes is linked to a higher percentage of survival than nondiabetic underlying diseases. Diabetes mellitus was the underlying illness in the majority of our patients, similar to other reports [32]. Recent studies have also focused on COVID-19, as a predisposing factor for mucormycosis [33,34]. The pathogenesis of mucormycosis shows that normal hosts’ mononuclear and polymorphonuclear phagocytes kill Mucorales by producing oxidative metabolites and defensins, so neutropenic patients and those with dysfunctional phagocytes are at risk of developing invasive mucormycosis [35,36]. There is profound lymphopenia in COVID-19, and viral replication exacerbates the inflammatory response and neutrophil and monocyte influx in the bloodstream in advanced infections [37]. As a result of the imbalance in neutrophil and lymphocyte activity, the patient becomes more susceptible to systemic fungal infections.

Similar to our results, a study in India reported a significant increase (nearly fourfold) in the number of FESS cases in their institution for mucormycosis removal, when comparing the last two years to the year 2021 [38]. FESS has been reported to be effective in the treatment of fungal ball. Surgery prevents endocranial complications in cases of fulminant invasive mycoses.

During the first wave in Iran, we believe that there was significant underreporting, and there was a surge of cases in the medical community during the first wave as well. The rise in mucormycosis cases, on the other hand, was interpreted as a coincidence rather than an outbreak. Due to the massive increase in cases, widespread media attention, and coverage that occurred during the following waves, we see an increase in the number of mucormycosis cases (Figure 1), which could be due to higher awareness and prompt investigation, which is also supported by a study in India [39]. Knowledge and awareness of the disease among both the general public and physicians can count as important factors for timely diagnosis and proper management of the disease [40–42]. Poorly controlled diabetes, excessive use of corticosteroids and possibly antibiotics, and environmental exposure may all play a role in the significantly higher prevalence of COVID-19-induced mucormycosis in Iran and also other countries [43]. Iran’s hot and humid climate may have aided the growth of Mucorales species, as was the case in India [44].

As demonstrated in our results, most cases developed mucormycosis two weeks after COVID-19. The disease is most commonly seen during the COVID-19 recovery period, implying that several factors contribute to fungal colonization. The time between COVID-19 and the initial diagnosis of mucormycosis was 10 to 15 days in most of the cases in a study by Rao et al. in India [45]. Patients may have overlooked mucormycosis symptoms (especially pain), confusing them with residual COVID-19 symptoms, and thus arrived at the hospital late. Furthermore, dental symptoms should also be addressed during initial hospital

Table 2: Continued.

| Variable | Total; \( N = 59 \) | Timeline | \( P \) value* | COVID-19 | \( P \) value* |
|----------|----------------|----------|----------------|----------|----------------|
| Bilateral FESS | 23 (39.0) | 4 (22.2) | 19 (46.3) | 6 (27.3) | 17 (45.9) |
| FESS + additional operation | 19 (32.2) | 7 (38.9) | 12 (29.3) | 11 (50.0) | 8 (21.6) *0.131 |
| Rt FESS | 12 (20.3) | 5 (27.8) | 7 (17.1) | 3 (13.6) | 9 (24.3) |
| Lt FESS | 3 (5.1) | 0 (0) | 3 (7.3) | 1 (4.5) | 2 (5.4) |
| Outcome | \( N = 59 \) | \( N = 59 \) | \( N = 59 \) | \( N = 59 \) | \( N = 59 \) |
| Discharge | 28 (49.1) | 8 (47.1) | 20 (50) | 12 (60.0) | 16 (43.2) *0.124 |
| Expired | 21 (36.8) | 8 (47.1) | 13 (32.5) | 4 (20.0) | 17 (45.9) |
| Relation of COVID-19 and mucormycosis | \( N = 59 \) | \( N = 59 \) | \( N = 59 \) | \( N = 59 \) | \( N = 59 \) |
| Not related to COVID-19 | 15 (25.4) | 9 (50) | 6 (14.6) | 15 (68.2) | 0 (0) |
| During COVID-19 | 12 (20.3) | 0 (0) | 12 (32.4) | 0 (0) | 12 (32.4) |
| Post-COVID-19 under 2 weeks | 15 (25.4) | 0 (0) | 15 (40.5) | 0 (0) | 15 (40.5) *<0.001 |
| Post-COVID-19 over 2 weeks | 7 (11.9) | 0 (0) | 7 (18.9) | 0 (0) | 7 (18.9) *<0.001 |
| Mucor onset before positive COVID-19 | 3 (5.1) | 0 (0) | 3 (8.1) | 0 (0) | 3 (8.1) |

* Additional operations such as maxillectomy, orbital exenteration, and frontal lobectomy.
visits, and nasal or sinus symptoms must be given priority with only magnetic resonance imaging (MRI). At a later stage of follow-up, patients may develop advanced maxillary disease (1–3 weeks) [45]. In order to limit tissue necrosis, it is critical to evaluate maxillary bone involvement on CT at an early stage.

A systematic review by Bhattacharyya et al. reported that COVID-19 causes a significant increase in mucormycosis in specific parts of the world. The overall mortality in our study was 36.8%, which is similar to other studies regarding orbital mucormycosis [46]. However, although most of our deceased cases had COVID-19, there was not any statistically significant association in this regard. COVID-19-associated mucormycosis death has been reported to be 16.3% based on a recent review by Muthu et al. [39].

Increased steroid use in COVID-19 patients could explain some of the increases in mucormycosis cases. Following the publication of the RECOVERY study’s randomized-controlled trial [1], steroid use increased. Patients hospitalized with COVID-19 who were given dexamethasone had a lower 28-day mortality rate than those who were given invasive mechanical ventilation or oxygen alone, according to the study. Even though steroids have no benefit in patients who do not require respiratory support in the trial, many COVID-19 patients who do not require mechanical ventilation have been treated with glucocorticoids, even at higher doses and for longer periods than the trial recommended [44]. In a review by Dilek et al. [47], steroids were given to 90.5 percent of patients with mucormycosis and COVID-19. Another risk factor for mucormycosis is diabetes. Steroids, which aggravate hyperglycemia in patients with diabetes mellitus, are the most common cause of drug-induced hyperglycemia [48]. Hyperglycemia caused by diabetes is thought to impair immune response, making it difficult to control the spread of invading pathogens [49].

Tropical and subtropical humid climates, as well as high environmental temperatures in most parts of India, appeared to play a role in disease prevalence [44]. The COVID-19 pandemic added to the growing mucormycosis pandemic by introducing new risk factors. India is currently dealing with a new wave of the COVID-19, which has posed a threat to the country’s healthcare system. India experienced another pandemic of mucormycosis during the COVID-19 pandemic.

Hypoxia of the tissues in COVID-19 disease is another factor that can play a role. The tissue damage is exacerbated by low oxygen levels in the tissues, as well as the partial infraction of fungal angioinvasion. Furthermore, the overuse of antibiotics, which is common in COVID-19 management, suppresses the normal bacterial flora, making it easier for fungi to establish and invade. Broad-spectrum antibiotic use is common in cases of COVID-19 with mucormycosis, according to a systematic review by Dilek et al. [47]. Antibiotics were used 74.6 percent of the time in COVID-19 cases, according to Langford et al. [50]. SEMI-COVID-19 analysis revealed that 78.1 percent of COVID-19 patients were prescribed antibiotics, with 34% of antibiotic prescriptions being inappropriate [51]. Despite the fact that antibiotic use has been shown to be ineffective, during the first wave of COVID-19 in India, an estimated 216 million excess antibiotic doses and 6.2 million azithromycin treatment courses were attributed to COVID-19 [44].

Recent studies suggest that COVID-19 is a procoagulable state with an increased risk of thrombotic events [37]. This procoagulable state is ideal for angioinvasion of Mucor invasion, which can lead to disseminated infections due to vessel thrombosis. Song et al. published a study in which they looked into a total of 99 patients who had fungal investigations after COVID-19 in China and discovered that about 5% of them were caused by Aspergillus species and 7% by Mucor species. They concluded that one of the most important pathogens is the impairment of T cell immunity in the presence of an underlying immunocompromised state [8]. Mehta and Pandey described a case of post-COVID-19 rhino-orbital mucormycosis, in which the patient received steroids according to protocol and developed mucormycosis as a result [52]. Regarding mucormycosis cases in our study, patients with COVID-19 had significantly lower platelet count compared to non-COVID-19 infected patients. According to their theory, alterations in immunity, particularly T cells and innate immunity, as well as the use of steroids, may be the cause of post-COVID-19 invasive fungal infection [52]. Amanda et al. from the United States and Chaudhary et al. from Delhi have made similar observations [53,54].

5. Conclusion

Even in the absence of comorbidities, physicians should be aware of the risk of secondary fungal infections in patients with COVID-19 who were treated with corticosteroids. Furthermore, the significance of a multidisciplinary approach should be taken into account.

Data Availability

The datasets generated and/or analysed during the current study are not publicly available because of patients details, but they are available from the corresponding author upon reasonable request.

Ethical Approval

All methods were carried out in accordance with relevant guidelines and regulations and approved by the Ethics committee of Shiraz University of Medical Science (IR.sums.med.rec.1400.526; Date 2 Jan 2022). Due to the retrospective nature of our study, inform consent was not obtained from the patients and the Ethics committee of Shiraz University of Medical Sciences waived the need for informed consent. The patients’ information was documented from their hospital records. Patients’ data were anonymized prior to analysis, and their confidentiality was secured by the researcher. All study protocols and data collection were performed in accordance with the Declaration of Helsinki and approved by the mentioned ethics committee.
References

[1] A. M. Sugar, "Mucormycosis," Clinical Infectious Diseases, vol. 14, no. 1, pp. S126–S129, 1992.

[2] G. Petrikkos, A. Skiadis, O. Lortholary, E. Rolilides, T. J. Walsh, and D. P. Kontoyiannis, "Epidemiology and clinical manifestations of mucormycosis," Clinical Infectious Diseases, vol. 54, no. 1, pp. S23–S34, 2012.

[3] R. Sahota, R. Gambhir, S. Anand, and A. Dixit, "Rhinocerebral mucormycosis: report of a rare case," Ethiopian Journal of Health Sciences, vol. 27, no. 1, pp. 85–90, 2017.

[4] A. Pahade, I. Chowdhury, A. K. Mittal, and A. Mowar, "Functional endoscopic sinus surgery for rhino-orbital mucormycosis in a pediatric patient with acute lymphocytic leukemia-anaesthetic considerations," Anesthesia & Analgesia, vol. 111, no. 4, pp. 599–606, 2010.

[5] P. Koehler, O. A. Cornely, B. W. Gottler et al., "COVID-19 associated pulmonary aspergillosis," Mycoses, vol. 63, no. 6, pp. 528–534, 2020.

[6] G. Chen, D. Wu, W. Guo et al., "Clinical and immunological features of severe and moderate coronavirus disease 2019," Journal of Clinical Investigation, vol. 130, no. 5, p. 2620, 2020.

[7] G. Song, G. Liang, and W. Liu, "Fungal Co-infections associated with global COVID-19 pandemic: a clinical and diagnostic perspective from China," Mycopathologia, vol. 185, no. 4, pp. 599–606, 2020.

[8] M. Salehi, K. Ahmadikia, H. Badali, and S. Khodavaisy, "Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran," Mycopathologia, vol. 185, no. 4, pp. 607–611, 2020.

[9] A. Vazin, R. Shahriarirad, N. Azadeh, N. Parandavar, and K. Kazemi, "Incidence, clinicomicrobiological characteristics, risk factors, and treatment outcomes of bacterial infections following liver transplantation in pediatrics: a retrospective cohort study," Archives Of Pediatric Infectious Disease, Article ID e118809.

[10] M. Shahriarirad, S. H. Ghotbabadi, and S. Aminnia, COVID-19 Pandemic in the Disguise of Multi System Inflammatory Syndrome in Children: A Case Series, Research Square, Durham, USA, 2021.

[11] G. Sabetian, S. Shahriarirad, M. Moghadami et al., High Post-infection Protection after COVID-19 Among Healthcare Workers: A Population-Level Observational Study Regarding SARS-CoV-2 Reinfection, Reactivation, and Re-positivity and its Severity, Research Square, Durham, USA, 2021.

[12] R. Shahriarirad, A. Erfani, K. Ranjar, B. Bazrafshan, and A. Mirahmadizadeh, "The mental health impact of COVID-19 outbreak: a Nationwide Survey in Iran," International Journal of Mental Health Systems, vol. 15, no. 1, 2021.

[13] A. Vazin, R. Shahriarirad, N. Azadeh, N. Parandavar, and K. Kazemi, "Incidence, clinicomicrobiological characteristics, risk factors, and treatment outcomes of bacterial infections following liver transplantation in pediatrics: a retrospective cohort study," Archives Of Pediatric Infectious Disease, Article ID e118809.

[14] M. Salehi, K. Ahmadikia, H. Badali, and S. Khodavaisy, "Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran," Mycopathologia, vol. 185, no. 4, pp. 607–611, 2020.

[15] A. Vazin, R. Shahriarirad, N. Azadeh, N. Parandavar, and K. Kazemi, "Incidence, clinicomicrobiological characteristics, risk factors, and treatment outcomes of bacterial infections following liver transplantation in pediatrics: a retrospective cohort study," Archives Of Pediatric Infectious Disease, Article ID e118809.

[16] M. Salehi, K. Ahmadikia, H. Badali, and S. Khodavaisy, "Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran," Mycopathologia, vol. 185, no. 4, pp. 607–611, 2020.

[17] A. M. Sugar, "Mucormycosis," Clinical Infectious Diseases, vol. 14, no. 1, pp. S126–S129, 1992.

[18] G. Petrikkos, A. Skiadis, O. Lortholary, E. Rolilides, T. J. Walsh, and D. P. Kontoyiannis, "Epidemiology and clinical manifestations of mucormycosis," Clinical Infectious Diseases, vol. 54, no. 1, pp. S23–S34, 2012.

[19] R. Shahriarirad, A. Erfani, K. Ranjar, B. Bazrafshan, and A. Mirahmadizadeh, "The mental health impact of COVID-19 outbreak: a Nationwide Survey in Iran," International Journal of Mental Health Systems, vol. 15, no. 1, 2021.

[20] R. Shahriarirad, A. Sanaei Dashi, and S. Hajiani Ghotbabadi, "Multisystem inflammatory syndrome with features of atypical kawasaki disease during the COVID-19 pandemic," Case Reports in Pediatrics, vol. 2021, Article ID 9950588, 4 pages, 2021.

[21] A. M. Sugar, "Mucormycosis," Clinical Infectious Diseases, vol. 14, no. 1, pp. S126–S129, 1992.

[22] G. Petrikkos, A. Skiadis, O. Lortholary, E. Rolilides, T. J. Walsh, and D. P. Kontoyiannis, "Epidemiology and clinical manifestations of mucormycosis," Clinical Infectious Diseases, vol. 54, no. 1, pp. S23–S34, 2012.

[23] R. Sahota, R. Gambhir, S. Anand, and A. Dixit, "Rhinocerebral mucormycosis: report of a rare case," Ethiopian Journal of Health Sciences, vol. 27, no. 1, pp. 85–90, 2017.

[24] A. Pahade, I. Chowdhury, A. K. Mittal, and A. Mowar, "Functional endoscopic sinus surgery for rhino-orbital mucormycosis in a pediatric patient with acute lymphocytic leukemia-anaesthetic considerations," Anesthesia & Analgesia, vol. 111, no. 4, pp. 599–606, 2010.

[25] P. Koehler, O. A. Cornely, B. W. Gottler et al., "COVID-19 associated pulmonary aspergillosis," Mycoses, vol. 63, no. 6, pp. 528–534, 2020.

[26] M. Salehi, K. Ahmadikia, H. Badali, and S. Khodavaisy, "Opportunistic fungal infections in the epidemic area of COVID-19: a clinical and diagnostic perspective from Iran," Mycopathologia, vol. 185, no. 4, pp. 607–611, 2020.
[28] J. C. Price and D. L. Stevens, “Hyperbaric oxygen in the treatment of rhinocerebral mucormycosis,” *The Laryngoscope*, vol. 90, no. 5, pp. 737–747, 1980.

[29] K. L. Peterson, M. Wang, R. F. Canalis, and E. Abemayor, “Rhinocerebral mucormycosis: evolution of the disease and treatment options,” *The Laryngoscope*, vol. 107, no. 7, pp. 855–862, 1997.

[30] Q. L. Luo, J. C. Orcutt, and L. S. Seifert, “Orbital mucormycosis with retinal and ciliary artery occlusions,” *British Journal of Ophthalmology*, vol. 73, no. 8, pp. 680–683, 1989.

[31] A. Maini, G. Tomar, D. Khanna, Y. Kini, H. Mehta, and N. Mishra, V. S. S. M. Mutya, A. Ohomu et al., “A caseseriesof rhinocerebral mucormycosis,” *The Laryngoscope*, vol. 92, no. 7, pp. 755–760, 1982.

[32] R.-S. Jiang and C.-Y. Hsu, “Endoscopic sinus surgery for rhinocerebral mucormycosis,” *American Journal of Rhinology*, vol. 13, no. 2, pp. 105–110, 1999.

[33] N. Mishra, V. S. S. Mutya, A. Thomas et al., “A case series of invasive mucormycosis in patients with COVID-19 infection,” *International Journal of Otorhinolaryngology and Head and Neck Surgery*, vol. 7, no. 5, pp. 867–870, 2021.

[34] A. Maini, G. Tomar, D. Khanna, Y. Kini, H. Mehta, and V. Bhagyasree, “Sino-orbital mucormycosis in a COVID-19 patient: a case report,” *International Journal of Surgery Case Reports*, vol. 82, Article ID 105957, 2021.

[35] A. R. Waldorf, “Pulmonary defense mechanisms against opportunistic fungal pathogens,” *Immunology Series*, vol. 47, pp. 243–271, 1989.

[36] A. R. Waldorf, N. Ruderman, and R. D. Diamond, “Specific susceptibility to mucormycosis in murine diabetes and bronchoalveolar macrophage defense against Rhizopus,” *Journal of Clinical Investigation*, vol. 74, no. 1, pp. 150–160, 1984.

[37] W. J. Wiersinga, A. Rhodes, A. C. Cheng, S. J. Peacock, and H. C. Prescott, “Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19),” *JAMA*, vol. 324, no. 8, pp. 782–793, 2020.

[38] V. Gadre, S. Hooli, S. Bage, and M. Gilvarkar, “O” he aftermath of COVID-19 pandemic: rhino-orbital mucormycosis,” *Indian Journal of Anaesthesia*, vol. 65, no. 7, pp. 548–553, 2021.

[39] V. Muthu, S. M. Rudramurthy, A. Chakrabarti, and R. Agarwal, “Epidemiology and pathophysiology of COVID-19-associated mucormycosis: India versus the rest of the world,” *Myopathologia*, vol. 186, no. 6, pp. 739–754, 2021.

[40] A. Erfani, R. Shahririrad, K. Ranbar, A. Mirahmadi-zadeh, and M. Moghadami, “Knowledge attitude and practice toward the novel coronavirus (COVID-19) outbreak: a population-based survey in Iran,” *Bulletin of the World Health Organization*, vol. 30, 2020.

[41] H. Ghoddusi Johari, S. Fatehpoor, P. Mardani, R. Shahririrad, and K. Ranbar, “An investigation of the Knowledge of general surgeons in Fars province in terms of the complications of central venous stenosis and thrombosis following insertion of a double-lumen subclavian catheter,” *Sadra Medical Journal*, vol. 9, no. 1, pp. 35–42, 2020.

[42] Z. Hosseini, R. Shahririrad, and B. Sarkari, “Cystic echi-nooccocis: Knowledge, attitude, and practices (KAP) among surgically operated cases in Fars province, southern Iran,” *Journal of Parasitology Research*, vol. 2021, pp. 1–7, 2021.

[43] A. K. Singh, R. Singh, S. R. Joshi, and A. Misra, “Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India,” *Diabetes & Metabolic Syndrome*, vol. 15, 2021.

[44] S. Gandra, S. Ram, and S. M. Levitz, *The “Black Fungus” in India: The Emerging Syndemic of COVID-19–Associated Mucormycosis*, American College of Physicians, Philadelphia, USA, 2021.

[45] V. U. S. Rao, G. Arakeri, G. Madikeri, A. Shah, R. S. Oeppen, and P. A. Brennan, “COVID-19 associated mucormycosis (CAM) in India: a formidable challenge,” *British Journal of Oral and Maxillofacial Surgery*, vol. 59, no. 9, pp. 1095–1098, 2021.

[46] S. Viterbo, M. Fasolis, P. Garzino-Demo et al., “Management and outcomes of three cases of rhinocerebral mucormycosis,” *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology & Endodontics*, vol. 112, no. 6, pp. e69–e74, 2011.

[47] A. Dilek, R. Ozaras, S. Ozkaya, M. Sunbul, E. I. Sen, and H. Leblebioglu, “COVID-19-associated mucormycosis: case report and systematic review,” *Travel Medicine and Infectious Disease*, vol. 44, Article ID 102148, 2021.

[48] A. E. Coutinho and K. E. Chapman, “The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights,” *Molecular and Cellular Endocrinology*, vol. 335, no. 1, pp. 2–13, 2011.

[49] A. Berbudi, N. Rahmadika, A. I. Tjahjadi, and R. Ruslami, “Type 2 diabetes and its impact on the immune system,” *Current Diabetes Reviews*, vol. 16, no. 5, pp. 442–449, 2020.

[50] B. J. Langford, M. So, S. Raybardhan et al., “Antibiotic prescribing in patients with COVID-19: rapid review and meta-analysis,” *Clinical Microbiology and Infections*, vol. 27, no. 4, pp. 520–531, 2021.

[51] J. Calderón-Parra, A. Muño-Miguez, A. D. Bendala-Estrada et al., “Inappropriate antibiotic use in the COVID-19 era: factors associated with inappropriate prescribing and secondary complications. Analysis of the registry SEMICOVID,” *PLoS One*, vol. 16, no. 5, Article ID e0251340, 2021.

[52] S. Mehta and A. Pandey, “Rhino-orbital mucormycosis associated with COVID-19,” *Cureus*, vol. 12, no. 9, 2020.

[53] A. Werthman-Ehrenreich, “Mucormycosis with orbital compartment syndrome in a patient with COVID-19,” *The American Journal of Emergency Medicine*, vol. 42, pp. e265–e268, 2021.

[54] A. Chowdhary, B. Tarai, A. Singh, and A. Sharma, “Multi-drug-resistant Candida auris infections in critically ill coronavirus disease patients, India, april-july 2020,” *Emerging Infectious Diseases*, vol. 26, no. 11, pp. 2694–2696, 2020.